9488f59b-105a-4c4b-844e-23498427b51f
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ADIPOGENESIS+0.300
- BILE_ACID_METABOLISM+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- HEME_METABOLISM+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- HEDGEHOG_SIGNALING+0.200
- PEROXISOME+0.200
- PROTEIN_SECRETION+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- XENOBIOTIC_METABOLISM+0.200
Top 10 suppressed
- G2M_CHECKPOINT-0.500
- E2F_TARGETS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- ANGIOGENESIS-0.200
- MYC_TARGETS_V2-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
- ALLOGRAFT_REJECTION-0.100
- APOPTOSIS-0.100
- CHOLESTEROL_HOMEOSTASIS-0.100
- COMPLEMENT-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A1IU-01A-11R-A14D-07 | — | B | 0.767 |
| 2 | BS_55P8HPYD | pilocytic astrocytoma | — | 0.709 |
| 3 | TCGA-78-7163-01A-12R-2066-07 | — | cohortA1 | 0.702 |
| 4 | SRR8613805 | — | F | 0.700 |
| 5 | BS_17WYVEEC | pilocytic astrocytoma | — | 0.695 |
| 6 | SRR35579847 | — | B | 0.691 |
| 7 | SRR8943024 | — | — | 0.687 |
| 8 | C3L-01889 | — | cohortA2 | 0.685 |
| 9 | SJEPD001531_D1.RNA-Seq | EPN | EPN Tumor | 0.683 |
| 10 | MNG123 | — | — | 0.681 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |